Varian patogenik BRCA1 atau BRCA2 meningkatkan risiko kanser keturunan; ia tidak mendiagnosis kanser. Varian yang mempunyai kepentingan tidak pasti tidak seharusnya mendorong pembedahan pencegahan. Keputusan negatif hanya merupakan keputusan negatif sebenar apabila ia menolak varian keluarga yang diketahui—jika tidak, risiko keturunan mungkin masih belum dapat dipastikan.
Perkara utama
- Keputusan positif bermaksud varian patogenik atau berkemungkinan patogenik telah dikenal pasti; kecenderungan keturunan bukanlah diagnosis kanser.
- Lima klasifikasi menerangkan varian genetik: patogenik, berkemungkinan patogenik, kepentingan tidak pasti, berkemungkinan jinak dan jinak.
- Risiko BRCA1 dalam kajian prospektif JAMA mencapai kira-kira 72% untuk kanser payudara dan 44% untuk kanser ovari menjelang umur 80 tahun dalam kalangan wanita yang membawa varian patogenik.
- Risiko BRCA2 dalam kajian yang sama mencapai kira-kira 69% untuk kanser payudara dan 17% untuk kanser ovari menjelang umur 80 tahun; ini ialah anggaran bagi kumpulan, bukan ramalan individu.
- Pengurusan VUS harus berdasarkan sejarah peribadi dan keluarga, bukan varian yang belum pasti; VUS sahaja tidak mewajarkan pembedahan pencegahan.
- Negatif sebenar bermaksud makmal tidak menemui varian patogenik khusus yang telah dikenal pasti dalam keluarga anda.
- Keputusan negatif yang tidak bermaklumat bermaksud ujian tidak menemui penjelasan bagi risiko keturunan yang disyaki; sejarah keluarga yang kuat masih boleh mewajarkan penilaian tambahan.
- Pewarisan keluarga biasanya memberikan setiap anak pembawa varian patogenik germline BRCA1 atau BRCA2 peluang 50% untuk mewarisi varian tersebut.
- Kaunseling genetik membantu menghubungkan varian yang tepat, liputan ujian, kedua-dua belah keluarga dan pilihan saringan atau pencegahan yang bergantung pada usia.
Apakah sebenarnya maksud keputusan ujian genetik BRCA?
Keputusan ujian genetik BRCA biasanya terbahagi kepada 3 kumpulan praktikal: positif, tidak pasti atau negatif. Keputusan keturunan yang positif mengenal pasti kerentanan terhadap kanser, manakala varian ketidakpastian signifikansi masih belum dapat dipastikan, dan keputusan negatif memerlukan konteks keluarga sebelum boleh dianggap meyakinkan.
A ujian BRCA germline memeriksa DNA, biasanya daripada sampel darah atau air liur di makmal, bukannya mengukur kepekatan protein. Keputusannya tidak boleh ditafsirkan seperti nilai dalam ng/mL: maklumat yang berguna secara klinikal ialah gen, varian yang tepat, pengelasan dan skop ujian.
Kebanyakan orang mempunyai 2 salinan BRCA1 dan 2 salinan BRCA2, dengan satu salinan bagi setiap gen diwarisi daripada setiap ibu bapa biologi. Perubahan berbahaya pada satu salinan boleh meningkatkan kerentanan terhadap kanser, tetapi perubahan sel tambahan biasanya menyumbang kepada perkembangan kanser—pewarisan bukan kiraan detik menuju penyakit.
Bagi individu hipotesis berusia 38 tahun yang tidak menghidap kanser, keputusan patogenik BRCA2 boleh mengubah perbincangan tentang saringan dan pencegahan pada masa hadapan tanpa mengesahkan sebarang diagnosis kanser semasa. Bagi seseorang yang sedang menerima rawatan kanser, penemuan keturunan yang sama juga boleh mempengaruhi kelayakan rawatan dan penilaian kanser pada masa hadapan.
Kantesti ialah seorang Penganalisis ujian darah AI untuk tafsiran makmal rutin, bukan pengganti makmal genetik klinikal. Maklumat tentang organisasi kami membantu membezakan peranan pendidikan kami daripada kerja pakar yang diperlukan untuk mentafsir keputusan kanser keturunan.
Butiran manakah dalam laporan makmal BRCA yang penting?
Butiran yang paling berguna dalam laporan BRCA ialah gen, varian yang tepat, pengelasan, jenis spesimen dan kaedah ujian. Makmal klinikal lazimnya menggunakan 5 pengelasan varian, dan perkataan “varian” sahaja tidak memberitahu anda sama ada sesuatu penemuan itu berbahaya.
Kerangka ACMG/AMP membezakan patogenik, berkemungkinan patogenik, tidak pasti kepentingannya, berkemungkinan jinak dan jinak penemuan (Richards et al., 2015). Varian patogenik dan berkemungkinan patogenik lazimnya menyokong laluan pengurusan klinikal yang sama; perbezaan itu menerangkan tahap keyakinan terhadap bukti, bukan dua peratusan risiko kanser yang berbeza.
Perihalan varian boleh merangkumi perubahan pada aras DNA yang bermula dengan c. and a protein-level consequence beginning with p. These are coordinates, not severity scores; two reports may describe the same change differently because they use different transcripts or historical naming conventions.
Look for both sequence analysis dan deletion/duplication analysis when evaluating a comprehensive BRCA1/BRCA2 test. Reading individual DNA changes and detecting missing or extra gene segments require complementary methods, so a report stating “sequencing negative” may not answer every relevant question.
A hypothetical report can contain 2 findings: a pathogenic BRCA1 variant and an unrelated BRCA2 VUS. Management follows the established pathogenic finding, not an average of the two classifications; our guide to categorical versus numerical results explains why laboratory result types require different reading strategies.
Maksud keputusan positif BRCA1: kecenderungan, bukan kepastian
BRCA1 positive meaning depends on the classification: a germline pathogenic or likely pathogenic BRCA1 variant indicates inherited cancer susceptibility. In a prospective study, women carrying pathogenic BRCA1 variants had an estimated 72% breast cancer risk and 44% ovarian cancer risk by age 80.
Kuchenbaecker et al. reported those age-80 estimates in JAMA, with 95% confidence intervals of 65–79% for breast cancer dan 36–53% for ovarian cancer (2017). The intervals describe uncertainty around population estimates; they do not mean an individual’s risk can be read directly from the laboratory report.
A hypothetical 30-year-old BRCA1 carrier should not interpret a 72% age-80 estimate as a 72% risk this year. Personal counseling separates near-term risk from longer-term risk and considers age, prior cancer, relatives’ diagnoses and any preventive procedures already completed.
BRCA1-associated breast cancers are more often triple-negative than breast cancers in the general population, but receptor status cannot be predicted from an inherited result alone. An existing cancer still requires its own pathological and receptor assessment; a genetic finding does not replace those separate tests.
One family can also have more than one inherited explanation for cancer, particularly when diagnoses cluster on both parental branches. For example, several colorectal and endometrial cancers may justify a separate assessment of Lynch syndrome results rather than assuming a BRCA1 finding explains every diagnosis.
Bagaimanakah risiko kanser mutasi BRCA2 berbeza?
BRCA2 mutation cancer risk includes breast and ovarian cancer susceptibility, with particular relevance to male breast, prostate and pancreatic cancer assessment. In the same prospective JAMA study, women carrying pathogenic BRCA2 variants had estimated risks of 69% for breast cancer and 17% for ovarian cancer by age 80.
The BRCA2 estimates had 95% confidence intervals of 61–77% for breast cancer dan 11–25% for ovarian cancer (Kuchenbaecker et al., 2017). BRCA2’s lower average ovarian cancer risk compared with BRCA1 helps explain why preventive ovary-and-tube removal is commonly discussed later for BRCA2 carriers.
A previous breast cancer creates a different risk question: the chance of another cancer in the opposite breast. Kuchenbaecker et al. estimated 20-year contralateral breast cancer risks of 26% for BRCA2 and 40% for BRCA1; those figures are not the same as first-cancer risk and should not be substituted for it.
Prostate screening discussions may begin around age 40 in men with pathogenic BRCA2 variants, depending on the applicable clinical pathway. PSA is a screening measurement rather than a symptom generator; our explanation of what elevated PSA means separates the laboratory number from a diagnosis.
Pancreatic surveillance is another area where eligibility criteria differ, including the importance assigned to family history. A hypothetical 52-year-old BRCA2 carrier with an affected first-degree relative needs a specialist discussion about MRI-based imaging or endoscopic ultrasound—not routine CA 19-9 testing as a substitute.
Apakah maksud varian BRCA yang mempunyai kepentingan tidak pasti?
A BRCA variant of uncertain significance, or VUS, means available evidence cannot establish whether a DNA change increases cancer risk. A VUS is not a positive result, and it should not independently determine preventive mastectomy or removal of the ovaries and fallopian tubes.
The ACMG/AMP standards state that a VUS tidak sepatutnya digunakan dalam membuat keputusan klinikal (Richards et al., 2015). Among the 5 classification categories, uncertainty is an evidence status—not a diagnosis, not a halfway-positive result and not a 50% probability that the variant causes cancer.
For example, a hypothetical 42-year-old with a BRCA1 VUS and no significant family history should not be offered risk-reducing surgery because of that VUS alone. Another 42-year-old with the same VUS and a substantial family history may qualify for intensified surveillance because of the history, not because the uncertain variant became actionable.
Ancestry can affect how often laboratories encounter uncertainty because population databases do not represent every group equally. Two people with the same cancer history can therefore receive different levels of interpretive certainty; this reflects evidence gaps and does not establish a biological difference in the seriousness of their results.
At Kantesti, we separate finding a genetic change from proving that the change warrants action. The same distinction helps readers understand common MTHFR variant findings, although MTHFR results and BRCA-associated cancer susceptibility have very different clinical implications.
Bolehkah klasifikasi VUS BRCA berubah kemudian?
A BRCA VUS can be reclassified when new evidence clarifies its clinical significance. Many reclassified VUS move toward benign categories, but neither the direction nor the timing can be promised for an individual finding; reinterpretation usually reviews existing DNA data rather than requiring another sample.
Useful new evidence can come from 3 broad sources: population frequency, carefully validated functional work and observations of the variant in families. A computer prediction alone is usually insufficient; expert curation weighs whether the evidence actually addresses the disease mechanism and meets classification standards.
Laboratories can disagree because their evidence differs or their interpretations were issued at different times. Record 2 separate dates when available—the original report date and the most recent classification date—and ask whether a specialist expert-panel assessment exists, rather than counting database entries as votes.
Routine testing of unaffected relatives for a VUS usually does not guide care, although a genetics team may arrange selected family studies to help classification. A hypothetical family with 3 affected relatives should not independently order VUS testing for everyone and interpret who carries it as proof of causation.
Ask which laboratory manages reinterpretation, how amended reports reach you and whether your contact details remain current; there is no universal recontact interval. Our discussion of inherited TTR variant interpretation illustrates the broader need to connect exact genetic findings with disease-specific evidence.
Bilakah keputusan BRCA negatif merupakan keputusan negatif sebenar?
A true negative BRCA result means testing did not find the specific pathogenic or likely pathogenic variant already identified in a biological relative. It removes the inherited risk attributable to that familial variant, but it does not eliminate ordinary cancer risk or unrelated risks from the other family branch.
Suppose a hypothetical mother has a confirmed pathogenic BRCA1 variant and her adult daughter’s targeted test excludes that exact variant. Before testing, the daughter generally had a 50%; afterward, she is not considered a carrier of that maternal finding and cannot pass that uncarried variant to her children.
A negative result becomes less definitive if nobody knows the affected relative’s exact finding. Bring a copy of the original family report rather than a verbal account of “BRCA positive”; a gene name alone cannot distinguish a pathogenic variant from a VUS or identify which change the laboratory should test.
An independently concerning paternal history can remain relevant despite a maternal true negative. For example, 2 close paternal relatives with early breast cancer may warrant separate risk assessment, because excluding one maternal variant does not explain another branch of the pedigree.
The logic of matching a relative’s exact finding also appears in family-based Alport genetic testing, although the genes and inheritance patterns differ. Ask for a written statement identifying which familial variant was excluded and what remaining screening recommendation follows from your own history.
Mengapakah keputusan BRCA negatif mungkin tidak memberikan maklumat?
Seorang negatif tidak informatif means no actionable BRCA finding was detected, but testing has not explained a suspicious personal or family cancer history. The result may reflect another gene, a technical limitation or a familial risk pattern that cannot currently be assigned to one detectable variant.
Testing an affected relative first usually provides more information than testing an unaffected relative. A hypothetical unaffected 35-year-old’s negative panel does not prove that her mother’s ovarian cancer lacked an inherited cause; testing the mother, when possible, can establish whether there is a familial finding to exclude.
A broader panel may consider genes such as PALB2, ATM, CHEK2, RAD51C, RAD51D and BRIP1, depending on the cancer pattern. These genes do not share identical cancer risks or prevention recommendations, so “panel positive” still requires gene-specific interpretation rather than applying the BRCA pathway to every result.
Older tests or limited consumer tests may assess only selected variants, whereas comprehensive clinical testing can include sequencing and deletion/duplication analysis. Our explanation of hidden carrier-screening limitations illustrates why a reassuring-looking result can still depend on methodology, although SMA uses a different genetic model.
Kantesti AI does not establish the completeness of a genetic assay or certify that a family’s inherited risk has been excluded. If a hypothetical family has 3 related cancers despite negative testing, clinical genetics can decide whether updated testing, another affected relative or a formal family-history risk model would answer the unresolved question.
Adakah penemuan BRCA dalam tumor bermakna ia diwarisi?
A BRCA variant found in tumor tissue is not automatically inherited. Tumor testing can detect acquired changes confined to cancer cells; germline testing examines a suitable non-tumor specimen to determine whether the finding is constitutional and relevant to relatives.
A tumor report may show a variant allele fraction near 50%, but that number does not prove germline origin. Tumor purity, copy-number changes and loss of the other gene copy can all shift the fraction; a percentage on a tumor report cannot replace a properly selected germline test.
Some oncology reports describe homologous recombination deficiency, or HRD, rather than a specific inherited variant. HRD can arise through more than one mechanism, and an HRD-positive result does not establish that a person or their children carry a pathogenic BRCA1 or BRCA2 variant.
After an allogeneic stem-cell transplant, a blood-derived DNA sample may reflect the donor, and saliva can also contain donor-derived cells. A hypothetical transplant recipient therefore needs the genetics laboratory to select an appropriate specimen—sometimes cultured skin fibroblasts—rather than assuming that 2 easily obtained samples answer the inheritance question.
The distinction between acquired and inherited DNA changes also matters in UBA1-related VEXAS testing, although VEXAS is a different condition. For a tumor BRCA finding, ask whether germline confirmation has been completed, is pending or was never requested.
Bilakah kaunseling genetik paling membantu?
Genetic counseling helps before testing and whenever a result could change screening, treatment or family testing. It is especially useful for pathogenic findings, unresolved VUS, limited negative tests and family patterns involving young diagnoses, ovarian cancer, male breast cancer or multiple related cancers.
A practical pedigree usually covers 3 generasi and records cancer type, age at diagnosis, biological relationships and both maternal and paternal branches. “Abdominal cancer” is less useful than a confirmed primary site; ovarian, pancreatic and metastatic cancers can otherwise be misremembered as the same diagnosis.
Small families, early deaths and few female relatives can hide hereditary breast-and-ovarian cancer patterns. A hypothetical father with 2 sons and no sisters can carry and transmit a BRCA variant even when the family has no obvious breast cancer cluster; paternal inheritance deserves the same attention as maternal inheritance.
Kantesti ialah seorang platform tafsiran ujian darah AI, not a genetic counseling service. Our guidance on age-appropriate family testing separates routine laboratory needs from predictive BRCA testing, which is generally deferred in children under 18 because management usually begins in adulthood.
Before an appointment, gather the actual family report, pathology details if available and your previous test methods. Use separate consent for each relative’s records; our discussion of family health consent explains why a shared family history does not give one person automatic permission to access everyone’s medical information.
Apakah susulan selepas keputusan BRCA patogenik?
A germline pathogenic BRCA result warrants a personalized prevention plan, not automatic surgery. Options include enhanced breast screening, discussion of risk-reducing procedures and assessment of other gene-associated cancers; age, reproductive plans, previous cancer and local guidance determine the timing.
Many high-risk pathways use annual breast MRI beginning around ages 25–30, with mammography commonly added around age 30, but national recommendations differ. The reason for combining methods is that each detects some findings the other can miss; more imaging is not simply a substitute for understanding age-specific benefit and false-positive risk.
NICE guideline NG241 lists risk-reducing removal of ovaries and fallopian tubes no earlier than age 35 for BRCA1 and 40 for BRCA2, with individualized assessment (NICE, 2024). Common clinical discussions use windows of approximately 35–40 and 40–45 years, respectively, after childbearing; these are planning ranges, not instructions for every carrier.
Removing only the fallopian tubes while delaying ovary removal has not been established as equivalent protection and remains a trial-based strategy in NICE guidance. Surgical menopause can affect symptoms, cardiovascular health and bones; our panduan kesihatan hormon wanita kami explains why prevention planning includes consequences beyond cancer risk.
Hormone treatment after premenopausal risk-reducing surgery may be considered until the usual menopause age, approximately 51, but previous breast cancer and other contraindications change that discussion. Bone-density assessment and evaluation of secondary bone-loss causes are distinct tasks; our guide to bone health laboratory assessment explains what routine tests can and cannot answer.
Apakah maksud keputusan BRCA bagi saudara-mara dan anak-anak?
Each child of a germline BRCA pathogenic-variant carrier usually has a 50% chance of inheriting the variant, regardless of sex. Adult relatives can consider targeted testing for the established family finding; inheriting susceptibility does not mean inheriting an existing cancer.
Four children do not imply that exactly 2 will inherit a parent’s BRCA variant. Each pregnancy is an independent event, so all, none or any number in between can inherit it; the 50% figure describes probability rather than a guaranteed family distribution.
A carrier’s siblings often have a peluang 50% of sharing the variant when a parent carries it, but that estimate should not be applied without checking the pedigree. Identifying which parent carries the finding helps determine which cousins, aunts and uncles should receive an invitation to discuss testing.
Reproductive options can include natural conception, prenatal diagnosis or IVF with preimplantation genetic testing for a known familial variant. These are preference-sensitive choices, not obligations; our explanation of reproductive genetic result counseling shows why gene-specific inheritance matters, although FMR1 repeat expansion behaves differently from BRCA inheritance.
A rare additional question arises when both partners carry pathogenic variants in BRCA2: each pregnancy has a 25% chance of inheriting pathogenic variants in both copies, which can cause a Fanconi anemia phenotype. Partner testing is not automatically required for every BRCA carrier, but ancestry, relatedness and reproductive planning can justify specialist assessment.
Bolehkah gejala atau penanda tumor mengesahkan kanser berkaitan BRCA?
Neither a BRCA result nor a tumor-marker concentration confirms that cancer is present. New symptoms need their own assessment, and a negative genetic result does not make them harmless; examination, imaging and sometimes tissue assessment answer a different question from inherited susceptibility testing.
CA-125 can rise in benign conditions and can remain normal in ovarian cancer, particularly earlier disease. Routine CA-125 and ultrasound screening have not demonstrated a mortality benefit sufficient to replace established risk-reduction discussions; our guide to CA-125 limits and symptoms explains why the usual 35 U/mL cutoff is not a cancer yes-or-no boundary.
CA 15-3 and CA 27-29 are not appropriate tests for deciding whether an unaffected BRCA carrier has developed breast cancer. A hypothetical carrier with a normal marker still needs assessment of a new breast lump; our explanation of CA 15-3 interpretation separates selected monitoring uses from screening.
Kantesti does not infer BRCA carrier status from routine laboratory markers. For example, a CA 19-9 result of 80 U/mL can have non-cancer explanations and cannot establish pancreatic cancer or inherited BRCA2 risk; our guide to CA 19-9 limitations explains the need for clinical and imaging context.
Persistent bloating, early satiety, unexplained weight loss, a new breast change or unexplained jaundice deserve timely medical review regardless of genetic classification. A hypothetical person with 3 weeks of new persistent symptoms should not wait for VUS reclassification or a routine genetics appointment before seeking a separate assessment.
Gunakan penjelasan AI tanpa menggantikan kaunseling genetik
AI explanations can support understanding, but they cannot independently classify a BRCA variant or authorize preventive surgery. A safe workflow preserves 3 essentials: the original laboratory report, specialist interpretation and a written follow-up plan that distinguishes inherited risk from evaluation of any current symptoms.
Kantesti ialah seorang platform tafsiran biomarker AI that explains routine laboratory findings, with interpretation generally available in about 60 seconds. That turnaround is not a timetable for genetic counseling, and our maklumat metodologi klinikal should not be read as validation of independent BRCA classification or hereditary cancer risk calculation.
Genetic reports can reveal information relevant to more than 1 orang, including biological relatives who have not chosen testing. Read our privasi dan amalan data before sharing sensitive documents, and avoid uploading another relative’s identifiable report without their permission.
The 2 research publications listed below concern our global routine-test report and RDW educational material; they are not BRCA cancer-risk studies, clinical prevention guidelines or evidence supporting surgery. The medical recommendations in this article instead draw on the ACMG/AMP classification standards, the prospective JAMA risk study and NICE familial ovarian cancer guidance.
Before acting, ask your genetics team to document whether the result is germline, which exact variant is actionable and whether a negative is true or uninformative. Our AI yang bertanggungjawab kami support keeping those clinical decisions with qualified professionals rather than treating an automated explanation as another laboratory classification.
Soalan lazim
Adakah keputusan ujian BRCA1 atau BRCA2 yang positif bermakna saya menghidap kanser?
Ujian BRCA1 atau BRCA2 germline yang positif mengenal pasti varian diwarisi yang patogenik atau berkemungkinan patogenik; ujian itu tidak mendiagnosis kanser. Dalam kajian prospektif oleh Kuchenbaecker et al. dalam JAMA, anggaran risiko kanser payudara menjelang usia 80 tahun ialah 72% bagi BRCA1 dan 69% bagi BRCA2 dalam kalangan wanita yang membawa varian patogenik. Angka tersebut ialah anggaran populasi, bukannya kebarangkalian bahawa kanser wujud pada masa ini. Diagnosis kanser semasa memerlukan penilaian klinikal yang berasingan.
Perlukah saya menjalani pembedahan pencegahan untuk varian BRCA yang tidak pasti kepentingannya?
Varian BRCA yang tidak diketahui kepentingan klinikalnya tidak sepatutnya menjadi satu-satunya faktor penentu pembedahan pencegahan. Kerangka ACMG/AMP mengelaskan varian kepada 5 kategori berasaskan bukti dan menyatakan bahawa varian yang tidak pasti tidak sepatutnya digunakan dalam pembuatan keputusan klinikal. Sejarah peribadi atau keluarga boleh menjadi alasan tersendiri untuk rawatan berisiko lebih tinggi, tetapi keputusan itu tidak boleh mengandaikan bahawa VUS bersifat patogenik. Pakar genetik boleh menerangkan bukti yang benar-benar menyokong sebarang prosedur yang dicadangkan.
Apakah perbezaan antara keputusan BRCA negatif sebenar dengan keputusan BRCA negatif yang tidak bermaklumat?
Keputusan negatif sebenar menolak varian BRCA patogenik atau berkemungkinan patogenik khusus yang telah dikenal pasti dalam saudara biologikal. Bagi anak kepada pembawa, keputusan ini boleh menjelaskan kebarangkalian pewarisan awal sebanyak 50% bagi varian yang dikenal pasti dalam keluarga tersebut. Keputusan negatif yang tidak bermaklumat tidak menemui varian yang boleh diambil tindakan tanpa memastikan sebab kanser berlaku dalam keluarga. Cabang keluarga yang lain, gen tambahan dan batasan ujian mungkin masih relevan selepas kedua-dua keputusan ini.
Bolehkah VUS BRCA menjadi positif kemudian?
BRCA VUS kemudiannya boleh diklasifikasikan semula sebagai patogenik atau berkemungkinan patogenik, tetapi juga boleh diklasifikasikan semula sebagai berkemungkinan benign atau benign. Pengklasifikasian semula menilai bukti dalam kerangka 5 kategori yang sama; ini tidak bermakna DNA individu tersebut telah berubah. Tiada tempoh akhir yang ditetapkan secara universal atau arah perubahan yang dijamin bagi sesuatu varian. Tanyakan kepada makmal asal atau perkhidmatan genetik tentang pengendalian laporan yang dipinda dan cara menghubungi semula.
Bolehkah saya mewarisi varian BRCA daripada bapa saya?
Varian patogenik BRCA1 atau BRCA2 boleh diwarisi daripada mana-mana ibu bapa kandung. Setiap anak kepada pembawa varian germline biasanya mempunyai peluang 50% untuk mewarisi varian tersebut, tanpa mengira sama ada pembawa itu ialah ibu atau bapa. Keluarga sebelah bapa yang mempunyai sedikit saudara perempuan mungkin menunjukkan sejarah kanser payudara atau ovari yang tidak begitu ketara walaupun membawa varian. Oleh itu, kaunseling genetik perlu mempertimbangkan kedua-dua cabang keluarga.
Adakah mutasi BRCA yang ditemukan dalam tumor saya bermakna anak-anak saya berisiko?
Mutasi BRCA yang ditemui dalam tisu tumor tidak membuktikan bahawa mutasi itu diwarisi. Walaupun pecahan alel varian tumor menghampiri 50%, asal usul germline tidak dapat dibuktikan dengan pasti kerana ketulenan tumor dan perubahan bilangan salinan mempengaruhi peratusan tersebut. Ujian germline menggunakan spesimen yang sesuai diperlukan untuk mengesahkan status pewarisan. Kebarangkalian transmisi 50% yang lazim hanya terpakai apabila ibu atau bapa membawa varian germline.
Adakah saya perlu mengulangi ujian BRCA negatif setiap tahun?
Ujian DNA BRCA berulang setiap tahun lazimnya tidak diperlukan kerana varian yang diwarisi tidak muncul begitu sahaja apabila seseorang semakin berusia. Keputusan negatif mungkin wajar dikaji semula jika ujian asal mempunyai skop terhad, varian keluarga baharu dikenal pasti atau saudara lain menghidap kanser yang berkaitan. Contohnya, ujian yang hanya melibatkan 3 varian terpilih tidak setara dengan penjujukan BRCA1/BRCA2 secara menyeluruh serta analisis penghapusan/penduplikasian. Tanyakan perkhidmatan genetik sama ada tafsiran semula, ujian keluarga bersasar atau panel yang berbeza dapat memberikan maklumat tambahan.
Dapatkan penjelasan tentang keputusan ujian darah anda
Muat naik laporan makmal anda dan AI Kantesti menerangkan setiap biomarker dalam bahasa mudah dalam beberapa saat. Digunakan oleh lebih daripada 2 juta orang di seluruh dunia.
Rujukan
- Klein, T., Mitchell, S., & Weber, H. (2026). Penganalisis Ujian Darah AI: 2.5M Ujian Dianalisis | Laporan Kesihatan Global 2026. Penyelidikan Perubatan AI Kantesti. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). Ujian Darah RDW: Panduan Lengkap tentang RDW-CV, MCV & MCHC. Penyelidikan Perubatan AI Kantesti. DOI
- Richards S et al. (2015). Piawaian dan garis panduan untuk tafsiran varian jujukan: saranan konsensus bersama American College of Medical Genetics and Genomics dan Association for Molecular Pathology. Genetik dalam Perubatan. DOI PubMed
- Kuchenbaecker KB et al. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. DOI PubMed
- National Institute for Health and Care Excellence (2024). Ovarian cancer: identifying and managing familial and genetic risk. NICE guideline NG241.
- 2J+Ujian dianalisis
- 127+negara
- 100+Bahasa
Mengenai pasukan perubatan
Isyarat Kepercayaan E-E-A-T
Pengalaman
Semakan klinikal yang diketuai oleh doktor terhadap aliran kerja tafsiran makmal.
Kepakaran
Fokus perubatan makmal tentang bagaimana biomarker berkelakuan dalam konteks klinikal.
Kewibawaan
Disemak secara perubatan oleh Dr. Thomas Klein, dengan sumbangan daripada Dr. Sarah Mitchell dan Prof. Dr. Hans Weber.
Kebolehpercayaan
Tafsiran berasaskan bukti dengan laluan susulan yang jelas untuk mengurangkan kebimbangan.
Penafian perubatan
Artikel ini adalah untuk tujuan pendidikan sahaja dan tidak merupakan nasihat perubatan. Sentiasa rujuk pembekal penjagaan kesihatan yang berkelayakan untuk keputusan diagnosis dan rawatan.
Diterbitkan · Hubungi pasukan editorial
Diterbitkan oleh Kantesti Ltd, berdaftar di England & Wales, nombor syarikat. 17090423, London, United Kingdom.
